Anti-resorptive monoclonal antibody | Blocks RANKL | Not bound to bone | Effect reverses on stopping - watch the rebound
WHERE DENOSUMAB SITS
Critical Must-Knows
- Mechanism: denosumab is a monoclonal antibody against RANKL (receptor activator of nuclear factor-kappa-B ligand). By mopping up RANKL it stops RANKL binding to RANK on osteoclast precursors, so osteoclasts do not form, function, or survive - bone resorption falls and bone density rises
- Not bound to bone: unlike bisphosphonates it is not stored in the skeleton, so the effect is fully reversible - this is the single most important difference
- Rebound fractures: stopping denosumab causes a sharp rebound in bone turnover and rapid bone loss, and some patients suffer multiple vertebral fractures - never stop it without a follow-on antiresorptive plan
- Dosing: 60mg subcutaneously every 6 months for osteoporosis (a higher, more frequent dose is used for giant cell tumour and bone metastases) - doses must not be delayed
- Also treats giant cell tumour of bone: denosumab shrinks and ossifies these RANKL-driven tumours and is used for unresectable or morbid lesions
Clinical Pearls
- "Check and correct calcium and vitamin D before every dose - denosumab can cause severe hypocalcaemia, especially in renal impairment
- "Denosumab is not cleared by the kidney, so unlike zoledronate it can be used (with care) in poor renal function - but hypocalcaemia risk is higher there
- "If you stop denosumab, give a bisphosphonate afterwards to blunt the rebound
- "It is a classic linking question against bisphosphonates: same end (less resorption), different means (RANKL vs hydroxyapatite uptake) and very different behaviour on stopping
Clinical Imaging
The disease denosumab treats, and how it is diagnosed and monitored
Critical Denosumab Exam Points
Mechanism
Denosumab is a monoclonal antibody to RANKL. RANKL is made by osteoblasts and binds RANK on osteoclast precursors to drive them to mature osteoclasts. By neutralising RANKL, denosumab stops osteoclast formation, function, and survival, so resorption falls and bone density rises. This is the classic basic-science answer - and the contrast with the bisphosphonate mechanism.
The Rebound After Stopping
Because denosumab is not bound to bone, its effect is fully reversible. Stopping it causes a sharp rebound in bone turnover and rapid bone loss, and some patients suffer multiple vertebral fractures within months. Never stop denosumab without a follow-on antiresorptive (usually a bisphosphonate), and never let a dose lapse.
Hypocalcaemia
Denosumab can cause severe hypocalcaemia, particularly in renal impairment or vitamin D deficiency. Correct calcium and vitamin D before every dose and check renal function. This is a more prominent and earlier risk than with oral bisphosphonates.
Shared Class Risks
Like all potent antiresorptives, denosumab carries the rare risks of osteonecrosis of the jaw and atypical femoral fracture - arrange dental review and counsel on thigh pain. It does not cause pill oesophagitis (it is an injection) and is not renally cleared.
Memory aids
RANKDenosumab Mechanism and Identity
| R | RANKL is the target Monoclonal antibody that binds and neutralises RANKL |
| A | Antibody, not bound to bone Effect is fully reversible - the key difference from bisphosphonates |
| N | No osteoclasts Blocks osteoclast formation, function, and survival |
| K | Kidney-safe clearance Not renally cleared, but watch hypocalcaemia in renal impairment |
| R | RANKL is the target Monoclonal antibody that binds and neutralises RANKL | N | No osteoclasts Blocks osteoclast formation, function, and survival |
| A | Antibody, not bound to bone Effect is fully reversible - the key difference from bisphosphonates | K | Kidney-safe clearance Not renally cleared, but watch hypocalcaemia in renal impairment |
Hook:Think RANK - it blocks RANKL, is an Antibody not stored in bone, leaves No osteoclasts, and is Kidney-safe to clear.
CRABDenosumab Complications
| C | Calcium low (hypocalcaemia) Correct calcium and vitamin D before every dose |
| R | Rebound fractures on stopping Multiple vertebral fractures - cover with a bisphosphonate |
| A | Atypical femoral fracture Rare, as with all potent antiresorptives - thigh-pain prodrome |
| B | Bone necrosis of the jaw Osteonecrosis of the jaw - dental review before starting |
| C | Calcium low (hypocalcaemia) Correct calcium and vitamin D before every dose | A | Atypical femoral fracture Rare, as with all potent antiresorptives - thigh-pain prodrome |
| R | Rebound fractures on stopping Multiple vertebral fractures - cover with a bisphosphonate | B | Bone necrosis of the jaw Osteonecrosis of the jaw - dental review before starting |
Hook:Watch the CRAB - Calcium low, Rebound fractures, Atypical femoral fracture, Bone necrosis of the jaw.
BRAVEDenosumab vs Bisphosphonates
| B | Bone binding differs Bisphosphonates bind hydroxyapatite; denosumab does not |
| R | Reversible effect Denosumab effect wears off; bisphosphonate effect lingers in bone |
| A | Antibody vs analogue Denosumab is a RANKL antibody; bisphosphonates are pyrophosphate analogues |
| V | Very different on stopping Rebound fractures with denosumab; drug holiday possible with bisphosphonates |
| E | Excretion route Denosumab not renally cleared; zoledronate avoided if eGFR low |
| B | Bone binding differs Bisphosphonates bind hydroxyapatite; denosumab does not | V | Very different on stopping Rebound fractures with denosumab; drug holiday possible with bisphosphonates |
| R | Reversible effect Denosumab effect wears off; bisphosphonate effect lingers in bone | E | Excretion route Denosumab not renally cleared; zoledronate avoided if eGFR low |
| A | Antibody vs analogue Denosumab is a RANKL antibody; bisphosphonates are pyrophosphate analogues |
Hook:Be BRAVE comparing the two - Bone binding, Reversible, Antibody, Very different on stopping, Excretion route.
Overview
Denosumab is a fully human monoclonal antibody that has become one of the most important anti-resorptive drugs in metabolic bone disease and orthopaedic oncology. Like bisphosphonates, it inhibits osteoclasts and so reduces bone resorption, raises bone mineral density, and lowers fracture risk. But it does this in a completely different way - by neutralising a single signalling protein, RANKL - and, crucially, it is not stored in the skeleton, so everything it does is reversible.
That reversibility is the heart of the topic. It gives denosumab some advantages (it works in renal impairment, and the effect can be measured cleanly) but also its single most dangerous property: when the drug is stopped or even just delayed, bone turnover rebounds and a cluster of vertebral fractures can follow. For the exam, three threads recur throughout: how it works (the RANK / RANKL / OPG system), what it treats (osteoporosis and giant cell tumour of bone, with strong evidence), and why you must never simply stop it (the rebound phenomenon).
Principles: The RANK / RANKL / OPG System
To understand denosumab you need the RANK / RANKL / OPG system - the master switch for osteoclast activity and a favourite basic-science viva.
- RANKL (receptor activator of nuclear factor-kappa-B ligand) is produced by osteoblasts and bone marrow stromal cells.
- RANK is the receptor on osteoclast precursors (and mature osteoclasts).
- When RANKL binds RANK, the precursors mature into active osteoclasts, survive longer, and resorb bone.
- Osteoprotegerin (OPG), also made by osteoblasts, is a natural decoy receptor: it binds RANKL and stops it reaching RANK, putting the brakes on resorption.
The balance of RANKL versus OPG therefore sets the rate of bone resorption. Denosumab works exactly like OPG - it is an antibody that binds RANKL and prevents it activating RANK. With RANKL neutralised, osteoclasts do not form, do not function, and do not survive, so resorption falls quickly and bone mineral density rises.
Denosumab vs Bisphosphonates - the high-yield comparison
| Feature | Denosumab | Bisphosphonates |
|---|---|---|
| Drug type | Fully human monoclonal antibody (IgG2) | Synthetic pyrophosphate analogues |
| Target / mechanism | Binds and neutralises RANKL (acts like OPG) | Bind hydroxyapatite, taken up by osteoclasts; nitrogen agents inhibit farnesyl pyrophosphate synthase |
| Bound to bone? | No - circulates, not stored in the skeleton | Yes - bind avidly to bone mineral and persist for years |
| Reversibility | Fully reversible - effect wears off in months | Long-lasting after stopping (basis of the drug holiday) |
| On stopping | Rebound bone turnover and risk of multiple vertebral fractures | Gradual offset; a drug holiday is acceptable in lower-risk patients |
| Renal handling | Not renally cleared - usable in renal impairment (watch hypocalcaemia) | Renally cleared - avoid IV zoledronate if eGFR less than 35 |
The line examiners want to hear: denosumab and bisphosphonates reach the same end (less osteoclast resorption) by different means, and they behave very differently when stopped - which is why denosumab must never simply be discontinued.
Indications, Dosing and Routes
Denosumab is given by subcutaneous injection, with the dose and frequency depending on the indication.
Denosumab Indications and Dosing
| Indication | Typical regimen | Notes |
|---|---|---|
| Postmenopausal and male osteoporosis | 60mg subcutaneously every 6 months | Marketed as Prolia; second-line or first-line where bisphosphonates are unsuitable |
| Glucocorticoid-induced osteoporosis | 60mg subcutaneously every 6 months | Effective option in patients on long-term steroids |
| Giant cell tumour of bone | 120mg subcutaneously monthly (with loading doses) | Marketed as Xgeva; for unresectable or morbid surgery, or to downstage before surgery |
| Bone metastases and myeloma (skeletal-related events) | 120mg subcutaneously every 4 weeks | Reduces skeletal-related events; higher hypocalcaemia and jaw osteonecrosis risk at this dose |
| Hypercalcaemia of malignancy | 120mg subcutaneously (refractory cases) | Used when bisphosphonates fail or are contraindicated by renal function |
Two practical points the exam loves:
- The higher, more frequent oncology dose (120mg monthly) carries a much greater risk of osteonecrosis of the jaw and hypocalcaemia than the osteoporosis dose (60mg every 6 months).
- Because denosumab is not renally cleared, it is an option in patients with poor renal function where intravenous zoledronate would be avoided - but you must watch even more carefully for hypocalcaemia.
Clinical Relevance
Denosumab turns up across the whole exam and in daily orthopaedic practice. In fracture liaison and bone-health clinics it is a key agent for secondary fracture prevention, especially when bisphosphonates are not tolerated or renal function is poor. In basic-science vivas the RANK / RANKL / OPG axis and the contrast with bisphosphonates are classic asks. In orthopaedic oncology denosumab is central to the modern management of giant cell tumour of bone, both to downstage tumours before surgery and to treat unresectable disease. And the rebound fracture problem - recognising it, preventing it, and never stopping the drug without cover - is a safety-critical theme examiners reward. Knowing when to start, how to dose, what to check before each injection, and how to stop safely is the practical core.
Evidence
Denosumab Reduces Fractures in Postmenopausal Osteoporosis (FREEDOM)
- Double-blind RCT, 7868 postmenopausal women, denosumab 60mg subcutaneously every 6 months vs placebo over 3 years
- New radiographic vertebral fracture cut by about 68 percent (2.3 vs 7.2 percent)
- Hip fracture reduced by about 40 percent (0.7 vs 1.2 percent) and nonvertebral fracture by about 20 percent
- No increase in cancer, infection, delayed fracture healing, or hypocalcaemia, and no jaw osteonecrosis in this 3-year study
Stopping Denosumab Causes Rebound Bone Loss and Vertebral Fractures (ECTS Position Statement)
- Systematic review and European Calcified Tissue Society position statement on stopping denosumab
- Discontinuation drives bone turnover above pre-treatment levels, with rapid bone loss and multiple vertebral fractures in some patients
- Higher risk with prevalent vertebral fractures, longer time off therapy, and larger gains then losses in hip bone density
- If denosumab is stopped, start an antiresorptive (usually a bisphosphonate) about 6 months after the last dose
Imaging Response of Giant Cell Tumour of Bone to Denosumab (Review)
- Denosumab inhibits the RANK / RANKL pathway that drives osteoclast-like giant cells in giant cell tumour of bone
- Imaging response includes a new sclerotic neocortex, matrix osteosclerosis, and reconstitution of subarticular bone
- Reduced FDG-PET avidity is an early sensitive sign of response
- Local recurrence after stopping denosumab and rare malignant transformation mean close specialist follow-up is needed
Complications and Safe Stopping
Denosumab Complications
| Complication | Who and when | Key point |
|---|---|---|
| Hypocalcaemia | Renal impairment, vitamin D deficiency, oncology dosing | Correct calcium and vitamin D before every dose; can be severe |
| Rebound vertebral fractures | After stopping or delaying a dose | Sharp turnover rebound; cover with a bisphosphonate when stopping |
| Osteonecrosis of the jaw | Oncology (120mg) dosing, dental work | Dental review before starting; far higher risk at oncology doses |
| Atypical femoral fracture | Long-duration potent antiresorptive use | Subtrochanteric or diaphyseal, transverse, thigh-pain prodrome |
| Infection / skin reactions | Reported in trials | RANKL has immune roles; cellulitis and eczema reported |
The Rebound Phenomenon - the must-know safety point
Because denosumab is not stored in bone, stopping it removes the brake on osteoclasts all at once. Bone turnover then rebounds above the pre-treatment level, bone density is lost rapidly over months, and a subset of patients sustain multiple spontaneous vertebral fractures. The risk is greatest in patients who already have vertebral fractures, who have been off therapy longer, and who gained a lot of hip bone density on treatment.
Never simply stop denosumab
Denosumab should not be discontinued without a plan. If it must be stopped, give a follow-on antiresorptive - usually a bisphosphonate - starting about 6 months after the last injection to blunt the rebound. A missed or delayed dose carries the same danger, so injections must be given on schedule. New back pain after stopping denosumab is a rebound vertebral fracture until proven otherwise.
Clinical Pearl
The cleanest viva line: "Unlike a bisphosphonate, denosumab is not bound to bone, so its effect is reversible. That is why there is no safe drug holiday - stopping it causes a rebound in bone turnover and can trigger multiple vertebral fractures, so I would either continue it long term or bridge with a bisphosphonate when stopping."
Osteonecrosis of the Jaw and Atypical Femoral Fracture
These rare class effects of potent antiresorptives also apply to denosumab. Arrange dental assessment before starting where feasible (the risk is much higher at the oncology dose), and counsel patients to report new thigh pain, which warrants radiographs of both femurs to look for an atypical femoral fracture.
Exam Viva Scenarios
Use these scenarios to practise clinical reasoning and management decisions
Mechanism and Comparison with Bisphosphonates (~3 min)
"A 72-year-old woman with osteoporosis and chronic kidney disease is started on denosumab because a bisphosphonate was unsuitable. The examiner asks how denosumab works, how it differs from bisphosphonates, and what you would check before each dose."
Mechanism: Denosumab is a fully human monoclonal antibody to RANKL. RANKL is made by osteoblasts and normally binds RANK on osteoclast precursors to drive them to mature, active osteoclasts. By neutralising RANKL, denosumab acts like the body's natural decoy osteoprotegerin, so osteoclasts do not form, function, or survive - resorption falls and bone density rises.
Difference from bisphosphonates: Bisphosphonates bind hydroxyapatite and are stored in bone for years, so their effect lingers. Denosumab is not bound to bone, so its effect is fully reversible. That is why it can be used in renal impairment - it is not renally cleared - but also why stopping it is dangerous.
Before each dose: I would confirm and correct calcium and vitamin D, because denosumab can cause severe hypocalcaemia, especially in chronic kidney disease. I would also ensure she is committed to continuing and arrange dental review.
Back Pain After Stopping Denosumab (~4 min)
"A 68-year-old woman stopped denosumab a year ago after several years of treatment because she moved and lost follow-up. She now presents with sudden severe back pain after bending. How do you proceed and what has gone wrong?"
What has gone wrong: She has stopped denosumab without follow-on therapy. Because denosumab is not bound to bone, its effect is reversible - stopping it causes a rebound in bone turnover above the pre-treatment level, rapid bone loss, and a high risk of multiple vertebral fractures. Her new back pain is a rebound vertebral fracture until proven otherwise.
Assessment: Focused history and examination, then imaging of the spine - radiographs and, where needed, MRI to confirm acute fractures and look for the multiple-level pattern typical of the rebound. I would assess for neurological compromise.
Management: Treat the fractures - analgesia, mobilisation, and spinal opinion if there is instability or neurology. Crucially, I would restart effective antiresorptive therapy promptly because she is in a high-turnover state - typically restarting denosumab or giving a bisphosphonate to control the rebound, alongside correcting calcium and vitamin D.
Prevention message: The lesson is that denosumab must never simply be stopped. Patients should either continue long term or be bridged with a bisphosphonate around 6 months after the last dose, and doses must never be allowed to lapse.
DENOSUMAB
Clinical summary
Mechanism
- •Fully human monoclonal antibody to RANKL
- •Neutralises RANKL, acting like natural osteoprotegerin (OPG)
- •Osteoclasts do not form, function, or survive - resorption falls
- •Not bound to bone, so the effect is fully reversible
Indications and Dose
- •Osteoporosis: 60mg subcutaneously every 6 months (Prolia)
- •Giant cell tumour of bone: 120mg monthly (Xgeva)
- •Bone metastases / myeloma: 120mg every 4 weeks
- •Usable in renal impairment - not renally cleared
Before Each Dose
- •Correct calcium and vitamin D - can cause severe hypocalcaemia
- •Check renal function (hypocalcaemia risk higher if impaired)
- •Arrange dental review (especially at oncology doses)
- •Confirm the patient will continue - never let a dose lapse
Red Flags
- •Stopping or delaying - rebound multiple vertebral fractures
- •If stopping, bridge with a bisphosphonate about 6 months after last dose
- •Thigh pain on long-term use - image both femurs for atypical fracture
- •Exposed jaw bone for more than 8 weeks - osteonecrosis of the jaw
Guidelines, Registries and Global Practice
- Osteoporosis guidelines (for example AAOS/AOA bone-health initiatives, NICE/NOGG in the UK, and endocrine society guidance) position denosumab as an effective antiresorptive, often second-line or for patients in whom bisphosphonates are unsuitable (for example renal impairment or intolerance), given its efficacy and non-renal clearance.
- The rebound phenomenon is now formally recognised across major bodies: the European Calcified Tissue Society and others advise never stopping denosumab without follow-on antiresorptive cover, usually a bisphosphonate started about 6 months after the last dose.
- In orthopaedic oncology, denosumab is established for giant cell tumour of bone - to downstage unresectable or morbid lesions and to control disease - with specialist guidance emphasising close imaging follow-up because the tumour can recur after cessation.
- Global practice variation largely reflects cost, access, and whether a bisphosphonate or denosumab is preferred first-line, rather than disagreement on the underlying biology - but the safety message about not stopping denosumab is universal.